ERBB3 and breast cancer: Recently, at ASCO 2015, an oral PI3Kα inhibitor, BYL719, was evaluated in combination with trastuzumab and a HER3 inhibitor, in a heavily pre treated HER2+ metastatic BC population (median number of previous therapy lines of 6).